Access the full text.
Sign up today, get DeepDyve free for 14 days.
G. Montalescot, A. Hof, F. Lapostolle, J. Silvain, J. Lassen, L. Bolognese, W. Cantor, Á. Cequier, M. Chettibi, S. Goodman, C. Hammett, K. Huber, M. Janzon, B. Merkely, R. Storey, U. Zeymer, O. Stibbe, P. Ecollan, Wim Heutz, E. Swahn, J. Collet, F. Willems, Caroline Baradat, M. Licour, A. Tsatsaris, E. Vicaut, C. Hamm (2014)
Prehospital ticagrelor in ST-segment elevation myocardial infarction.The New England journal of medicine, 371 11
M. Cavender, M. Sabatine (2014)
Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trialsThe Lancet, 384
R. Stables (2015)
Heparin may be hard to beat: however much you are willing to spend on bivalirudin.JACC. Cardiovascular interventions, 8 1 Pt B
R. Mehran, Alexandra Lansky, B. Witzenbichler, G. Guagliumi, J. Peruga, B. Brodie, D. Dudek, R. Kornowski, F. Hartmann, B. Gersh, S. Pocock, S. Wong, E. Nikolsky, L. Gambone, Lynn Vandertie, H. Parise, G. Dangas, G. Stone (2009)
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trialThe Lancet, 374
A. Heestermans, J. Werkum, D. Taubert, T. Seesing, N. Beckerath, C. Hackeng, E. Schömig, F. Verheugt, J. Berg (2008)
Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction.Thrombosis research, 122 6
GD Dangas, A Caixeta, R Mehran (2011)
Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS‐AMI) Trial Investigators. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction, 123
Jayant Rai, Preeti Yadav (2015)
Brain targeted drug delivery system: An overview of recent developments and challengesJournal of Pharmaceutical Care & Health Systems
G. Parodi, Benedetta Bellandi, R. Valenti, A. Migliorini, R. Marcucci, N. Carrabba, L. Giurlani, G. Gensini, R. Abbate, D. Antoniucci (2014)
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.American heart journal, 167 6
M. Koutouzis, B. Lagerqvist, S. James, E. Omerovic, G. Matejka, L. Grip, P. Albertsson (2011)
Unfractionated heparin administration in patients treated with bivalirudin during primary percutaneous coronary intervention is associated lower mortality and target lesion thrombosis: a report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)Heart, 97
Yaling Han, Jincheng Guo, Yang Zheng, Hong-yun Zang, X. Su, Yu Wang, Shaoliang Chen, Tieming Jiang, Ping Yang, Ji-yan Chen, D. Jiang, Quanmin Jing, Zhenyang Liang, Haiwei Liu, Xin Zhao, Jing Li, Yi Li, Bo Xu, G. Stone (2015)
Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.JAMA, 313 13
G. Parodi, R. Valenti, Benedetta Bellandi, A. Migliorini, R. Marcucci, V. Comito, N. Carrabba, A. Santini, G. Gensini, R. Abbate, D. Antoniucci (2013)
Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.Journal of the American College of Cardiology, 61 15
R. Piccolo, C. Biase, C. D'Anna, B. Trimarco, F. Piscione, G. Galasso (2015)
Early stent thrombosis with bivalirudin in patients undergoing percutaneous coronary interventionThrombosis and Haemostasis, 113
J. Aoki, A. Lansky, R. Mehran, J. Moses, Michel Bertrand, B. McLaurin, David Cox, A. Lincoff, E. Ohman, Harvey White, H. Parise, Martin Leon, G. Stone (2009)
Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents: The Acute Catheterization and Urgent Intervention Triage Strategy TrialCirculation, 119
M Valgimigli, E Frigoli, S Leonardi (2015)
MATRIX Investigators. Bivalirudin or unfractionated heparin in acute coronary syndromes, 373
A Shahzad, I Kemp, C Mars (2014)
HEAT‐PPCI trial investigators. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT‐PPCI): An open‐label, single centre, randomised controlled trial, 384
P. Steg, A. Hof, C. Hamm, P. Clemmensen, F. Lapostolle, P. Coste, J. Berg, P. Grunsven, G. Eggink, L. Nibbe, U. Zeymer, Marco Orto, H. Nef, J. Steinmetz, L. Soulat, K. Huber, E. Deliargyris, D. Bernstein, Diana Schuette, J. Prats, T. Clayton, S. Pocock, M. Hamon, P. Goldstein (2013)
Bivalirudin started during emergency transport for primary PCI.The New England journal of medicine, 369 23
J. Brandt, C. Payne, S. Wiviott, G. Weerakkody, N. Farid, D. Small, J. Jakubowski, H. Naganuma, K. Winters (2007)
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.American heart journal, 153 1
G Montalescot, AW van 't Hof, F Lapostolle (2014)
ATLANTIC Investigators. Prehospital ticagrelor in ST‐segment elevation myocardial infarction, 371
P. Clemmensen, S. Wiberg, A. Hof, E. Deliargyris, P. Coste, J. Berg, C. Cavallini, M. Hamon, D. Dudek, U. Zeymer, X. Tabone, S. Kristensen, D. Bernstein, P. Anthopoulos, J. Prats, P. Steg (2015)
Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography).JACC. Cardiovascular interventions, 8 1 Pt B
R. Iijima, G. Ndrepepa, J. Mehilli, R. Byrne, S. Schulz, F. Neumann, G. Richardt, P. Berger, A. Schömig, A. Kastrati (2008)
Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention.European heart journal, 30 3
A. Shahzad, I. Kemp, Christine Mars, Keith Wilson, Claire Roome, R. Cooper, M. Andron, C. Appleby, M. Fisher, A. Khand, B. Kunadian, J. Mills, J. Morris, W. Morrison, S. Munir, N. Palmer, R. Perry, D. Ramsdale, P. Velavan, R. Stables (2014)
Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trialThe Lancet, 384
D. Alexopoulos, I. Xanthopoulou, V. Gkizas, G. Kassimis, K. Theodoropoulos, G. Makris, N. Koutsogiannis, A. Damelou, Grigorios Tsigkas, P. Davlouros, G. Hahalis (2012)
Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial InfarctionCirculation: Cardiovascular Interventions, 5
G. Montalescot, L. Bolognese, D. Dudek, P. Goldstein, C. Hamm, J. Tanguay, J. Berg, Debra Miller, T. Costigan, J. Goedicke, J. Silvain, P. Angioli, J. Legutko, Margit Niethammer, Z. Motovska, J. Jakubowski, G. Cayla, L. Visconti, E. Vicaut, P. Widimsky (2013)
Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.The New England journal of medicine, 369 11
C. Cannon, S. Husted, R. Harrington, B. Scirica, H. Emanuelsson, G. Peters, R. Storey (2007)
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.Journal of the American College of Cardiology, 50 19
G. Dangas, A. Caixeta, R. Mehran, H. Parise, A. Lansky, Ecaterina Cristea, B. Brodie, B. Witzenbichler, G. Guagliumi, J. Peruga, D. Dudek, Martin Möeckel, G. Stone (2011)
Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial InfarctionCirculation, 123
Y Han, J Guo, Y Zheng (2015)
BRIGHT Investigators. Bivalirudin vs. heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: The BRIGHT randomized clinical trial, 313
E. Navarese, V. Schulze, F. Andreotti, M. Kowalewski, M. Kołodziejczak, D. Kandzari, T. Rassaf, B. Górny, M. Brockmeyer, C. Meyer, S. Berti, J. Kubica, M. Kelm, M. Valgimigli (2015)
Comprehensive meta-analysis of safety and efficacy of bivalirudin versus heparin with or without routine glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndrome.JACC. Cardiovascular interventions, 8 1 Pt B
G Montalescot, L Bolognese, D Dudek (2013)
ACCOAST Investigators. Pretreatment with prasugrel in non‐ST‐segment elevation acute coronary syndromes, 369
R. Shelton, C. Eftychiou, K. Somers, A. Liu, Natalie Burton-Wood, Michelle Anderson, L. Makri, J. Blaxill, J. Mclenachan, S. Wheatcroft, J. Greenwood, D. Blackman (2013)
Bivalirudin in patients undergoing primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: outcomes in a large real-world population.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 9 1
Background Prolonging infusions may abrogate the acute stent thrombosis (ST) associated with bivalirudin use during primary PCI but at an increased cost. We hypothesized that continuing the bivalirudin infusion commenced during the procedure at the PCI recommended dose until infusion end would prevent excess early ST. Methods Baseline demographics, procedural data and outcomes were gathered prospectively on 1395 consecutive patients undergoing primary PCI. The choice of bivalirudin versus heparin was at the cardiologist's discretion. Local protocol recommended continuation of the procedural bivalirudin at the PCI dose until infusion end. Results Patients' mean age was 62.8 ± 13.1years with 11.4% presenting with shock. The majority of patients underwent PCI using bivalirudin with fewer using heparin (87.7 vs. 12.3%, P < 0.0001). Glycoprotein inhibitor bailout rates were 6.1% with bivalirudin and 36.3% with heparin (P < 0.0001). Calculated on an individual patient basis the median intra‐procedure duration of the bivalirudin infusion was 30(IQR 21‐43) minutes and post‐procedure 49(32–66) minutes. The acute (<24‐hours) ST rates were 4/1224 with bivalirudin ± GPI (0.3%) and 0/171 with heparin ± GPI (0%, P = 0.41). The sub‐acute (24‐hours to 30‐days) ST rates were 3/1224 for bivalirudin ± GPI (0.3%) and 2/171 with heparin ± GPI (1.2%, P = 0.11). In total the early (<30‐days) ST rates were 7/1224 for bivalirudin ± GPI (0.6%) and 2/171 with heparin ± GPI (1.2%, P = 0.31). Acute ST was significantly more likely to occur in clopidogrel‐loaded patients than prasugrel/ticagrelor patients (2.7 vs. 0.5%, P = 0.003). Conclusion Continuing the bivalirudin infusion commenced during the procedure at the PCI recommended dose until infusion end combined with potent P2Y12 inhibitors ameliorates excess early stent thrombosis. (J Interven Cardiol 2016;29:129–136)
Journal of Interventional Cardiology – Wiley
Published: Apr 1, 2016
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.